202 related articles for article (PubMed ID: 26146893)
1. The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Krysiak R; Gilowski W; Szkrobka W; Okopien B
Cardiovasc Ther; 2015 Oct; 33(5):282-7. PubMed ID: 26146893
[TBL] [Abstract][Full Text] [Related]
2. Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia.
Krysiak R; Szkróbka W; Okopień B
Pharmacol Rep; 2019 Feb; 71(1):61-66. PubMed ID: 30469130
[TBL] [Abstract][Full Text] [Related]
3. Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia.
Krysiak R; Szkróbka W; Okopień B
J Clin Pharmacol; 2019 Jan; 59(1):83-89. PubMed ID: 30129670
[TBL] [Abstract][Full Text] [Related]
4. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Krysiak R; Okopien B
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
[TBL] [Abstract][Full Text] [Related]
5. Impact of Macroprolactinemia on Cardiometabolic Effects of Atorvastatin in Women With Hypercholesterolemia.
Krysiak R; Kowalcze K; Okopień B
Am J Cardiol; 2019 Oct; 124(8):1207-1212. PubMed ID: 31409451
[TBL] [Abstract][Full Text] [Related]
6. The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study.
Krysiak R; Okrzesik J; Szkrobka W; Okopień B
Pharmacol Rep; 2016 Feb; 68(1):185-9. PubMed ID: 26721371
[TBL] [Abstract][Full Text] [Related]
7. Different effects of atorvastatin on metabolic and cardiovascular risk factors in hypercholesterolemic women with normal thyroid function and subclinical hypothyroidism.
Krysiak R; Gilowski W; Okopien B
Exp Clin Endocrinol Diabetes; 2015 Mar; 123(3):182-6. PubMed ID: 25658659
[TBL] [Abstract][Full Text] [Related]
8. The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study.
Krysiak R; Okrzesik J; Okopien B
Endocrine; 2015 May; 49(1):242-9. PubMed ID: 25239203
[TBL] [Abstract][Full Text] [Related]
9. The effect of testosterone on cardiometabolic risk factors in atorvastatin-treated men with late-onset hypogonadism.
Krysiak R; Gilowski W; Okopień B
Pharmacol Rep; 2016 Feb; 68(1):196-200. PubMed ID: 26721373
[TBL] [Abstract][Full Text] [Related]
10. Alternative Treatment Strategies in Women Poorly Tolerating Moderate Doses of Bromocriptine.
Krysiak R; Szkróbka W; Okopień B
Exp Clin Endocrinol Diabetes; 2017 Jun; 125(6):360-364. PubMed ID: 28073129
[No Abstract] [Full Text] [Related]
11. The Effect of Metformin and Metformin-Testosterone Combination on Cardiometabolic Risk Factors in Men with Late-onset Hypogonadism and Impaired Glucose Tolerance.
Krysiak R; Gilowski W; Okopien B
Exp Clin Endocrinol Diabetes; 2015 Nov; 123(10):608-13. PubMed ID: 26600057
[TBL] [Abstract][Full Text] [Related]
12. Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis.
Krysiak R; Kowalcze K; Okopień B
Pharmacology; 2023; 108(3):255-264. PubMed ID: 36878199
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Testosterone and Fenofibrate, Administered Alone or in Combination, on Cardiometabolic Risk Factors in Men with Late-Onset Hypogonadism and Atherogenic Dyslipidemia.
Krysiak R; Gilowski W; Okopien B
Cardiovasc Ther; 2015 Oct; 33(5):270-4. PubMed ID: 26031507
[TBL] [Abstract][Full Text] [Related]
14. Impaired Cardiometabolic Effects of Bromocriptine in Men With Early-Onset Androgenic Alopecia.
Krysiak R; Basiak M; Szkróbka W; Okopień B
J Clin Pharmacol; 2023 Mar; 63(3):345-351. PubMed ID: 36222207
[TBL] [Abstract][Full Text] [Related]
15. Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study.
Krysiak R; Kowalcze K; Okopień B
Cardiology; 2022; 147(5-6):497-506. PubMed ID: 36195057
[TBL] [Abstract][Full Text] [Related]
16. The effect of atorvastatin on cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia: A pilot study.
Krysiak R; Kowalcze K; Bednarska-Czerwińska A; Okopień B
Pharmacol Rep; 2019 Jun; 71(3):417-421. PubMed ID: 31003151
[TBL] [Abstract][Full Text] [Related]
17. The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome.
Krysiak R; Szkróbka W; Okopień B
Pharmacol Rep; 2021 Feb; 73(1):261-268. PubMed ID: 32696349
[TBL] [Abstract][Full Text] [Related]
18. The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.
Kashi Z; Mahrooz A; Kianmehr A; Alizadeh A
PLoS One; 2016; 11(3):e0151543. PubMed ID: 26978661
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia.
Krysiak R; Kowalcze K; Okopień B
J Clin Pharmacol; 2023 Aug; 63(8):886-894. PubMed ID: 37042432
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin delays the glucose clearance rate in hypercholesterolemic rabbits.
Cheng D; Wang Y; Gao S; Wang X; Sun W; Bai L; Cheng G; Chu Y; Zhao S; Liu E
Biomed Pharmacother; 2015 May; 72():24-9. PubMed ID: 26054671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
